• Baird Medical entered a strategic partnership with China-based Alpmed to co-develop and commercialize next-generation irreversible electroporation ablation devices globally.
• Baird Medical will lead global regulatory filings, including the US, with a 510(k) submission targeted by end-2026 and potential clearance in 2027.
• Baird Medical secured worldwide commercialization rights for the first co-developed IRE system aimed at soft-tissue solid tumors.
• Deal broadens Baird Medical’s portfolio beyond its microwave ablation thyroid franchise as it pushes expansion into the US market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baird Medical Investment Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100830PRIMZONEFULLFEED9806759) on August 10, 2026, and is solely responsible for the information contained therein.